The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling.

MLA

Xie, Zhifu, et al. “The Triterpenoid Sapogenin (2α-OH-Protopanoxadiol) Ameliorates Metabolic Syndrome via the Intestinal FXR/GLP-1 Axis through Gut Microbiota Remodelling.” Cell Death & Disease, vol. 11, no. 9, Sept. 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41419-020-02974-0.

APA

Xie, Z., Jiang, H., Liu, W., Zhang, X., Chen, D., Sun, S., Zhou, C., Liu, J., Bao, S., Wang, X., Zhang, Y., Li, J., Hu, L., & Li, J. (2020). The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling. Cell Death & Disease, 11(9), 1–10. https://doi.org/10.1038/s41419-020-02974-0

Chicago

Xie, Zhifu, Haowen Jiang, Wei Liu, Xinwen Zhang, Dakai Chen, Shuimei Sun, Chendong Zhou, et al. 2020. “The Triterpenoid Sapogenin (2α-OH-Protopanoxadiol) Ameliorates Metabolic Syndrome via the Intestinal FXR/GLP-1 Axis through Gut Microbiota Remodelling.” Cell Death & Disease 11 (9): 1–10. doi:10.1038/s41419-020-02974-0.